EpiVario
Philadelphia, US · Founded 2017 · Delaware corporation
Find your way into EpiVario
794 people in our graph share verified history with the EpiVario team — schools, employers, funds. One of them is your warm intro.
Paul Bragielunlockedknows Thomas Kim · together at University of Illinois Urbana-Champaign (overlapped)
%20(1).png)
×5knows the team · via University of Pennsylvania
knows the team · via Georgia Institute of Technology
knows the team · via University of Illinois Urbana-Champaign
×2knows the team · via Freie Universität Berlin
×2knows the team · via University of Pennsylvania School of Medicine
EpiVario is a biotechnology company developing small-molecule ACSS2 inhibitors that target a neuroepigenetic process involved in long-term memory formation, aimed at treating PTSD and substance use disorders. Spun out of the University of Pennsylvania's Epigenetics Institute, it develops pharmacotherapeutics for memory-related psychiatric and addiction disorders.
Founders & leadership
EpiVario was founded in 2017 by Shelley Berger and Philipp Mews.
SB
Shelley BergerCo-Founder
PM
Philipp MewsinCo-FounderPhilipp Mews is co-founder of EpiVario, a biotechnology company developing small-molecule ACSS2 inhibitors for memory-related psychiatric and addiction disorders, spun out from the University of Pennsylvania's Epigenetics Institute where his research focused on neuroepigenetics and metabolism.
TK
Thomas KiminPresident and CEOThomas Kim is an executive and attorney with experience across life sciences companies ranging from startups to large organizations. He has led a university biotech spinout through seed funding and preclinical development, and previously guided a biotech startup through a merger that resulted in a NASDAQ-listed company with over 300 employees; he has also in-licensed technologies from universities and major companies and negotiated partnerships with pharmaceutical firms.
ES
Eric SchultenoverNamed on SEC filing
MD
Michael DishowitzNamed on SEC filing
Reported raises · per SEC filings
Form D private placements$1.1M disclosed across 4 rounds · 2018–2024
▶$125KraisedJan 2024 · 3 investors · PharmaceuticalsRule 506(b)
▶$125KraisedJan 2024 · 3 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Eric SchultenoverDirector
- Yi-Yen ChenDirector
- Thomas KimExecutive Officer, Director
- Offering amount
- $1.5M
- Amount sold
- $125K
- Minimum investment
- $25K
- First sale
- Jan 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$135KraisedSep 2022 · 3 investors · PharmaceuticalsRule 506(b)
▶$135KraisedSep 2022 · 3 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Eric SchultenoverDirector
- Michael DishowitzDirector
- Thomas KimExecutive Officer, Director
- Offering amount
- $1.5M
- Amount sold
- $135K
- Proceeds to insiders
- $48K
- First sale
- Aug 2022
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$233KraisedAug 2021 · 9 investors · PharmaceuticalsRule 506(b)
▶$233KraisedAug 2021 · 9 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Thomas KimExecutive Officer, Director
- Eric SchultenoverDirector
- Michael DishowitzDirector
- Offering amount
- $1.3M
- Amount sold
- $233K
- Minimum investment
- $100K
- First sale
- Jul 2021
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$599.5KraisedMar 2020 · 23 investors · PharmaceuticalsRule 506(b)
▶$599.5KraisedMar 2020 · 23 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Thomas KimExecutive Officer, Director
- Eric SchultenoverDirector
- Michael DishowitzDirector
- Offering amount
- $750K
- Amount sold
- $599.5K
- First sale
- Sep 2018
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 3
by search overlapBioworld13 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Eli Lilly13 shared keywordsEli Lilly discovers, develops, manufactures, and markets human pharmaceutical products across cardiometabolic, oncology, immunology, and neuroscience therapeutic areas, selling to healthcare providers and patients in approximately 90 countries through wholesalers, direct sales representatives, and digital platforms.
Epi Biologics10 shared keywordsEpibiologics develops protein degradation medicines using protein sciences and antibody engineering capabilities.
Companies competing with EpiVario for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2022 | $260K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does EpiVario do?
- EpiVario is a biotechnology company developing small-molecule ACSS2 inhibitors that target a neuroepigenetic process involved in long-term memory formation, aimed at treating PTSD and substance use disorders. Spun out of the University of Pennsylvania's Epigenetics Institute, it develops pharmacotherapeutics for memory-related psychiatric and addiction disorders.
- Who founded EpiVario?
- EpiVario was founded by Shelley Berger, Philipp Mews in 2017.
- How much funding has EpiVario raised?
- EpiVario has disclosed $1.1M raised across 4 rounds.
- Where is EpiVario headquartered?
- EpiVario is headquartered in Philadelphia, US.